Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Novavax, Inc. (NVAX)

8.04 +0.12 (+1.45%)
At close: May 1 at 4:00:00 PM EDT
8.06 +0.02 (+0.21%)
After hours: May 1 at 7:59:35 PM EDT
Trade Novavax on Coinbase
Chart Range Bar
Loading chart for NVAX

News headlines Novavax is transitioning to a licensing model while awaiting key vaccine data. The stock has shown modest year-to-date gains but faces significant valuation challenges and declining revenue expectations.

Novavax is transitioning to a licensing model while awaiting key vaccine data. The stock has shown modest year-to-date gains but faces significant valuation challenges and declining revenue expectations.

Updated 22m ago · Powered by Yahoo Scout
  • Previous Close 7.93
  • Open 7.90
  • Bid 8.01 x 500
  • Ask 8.07 x 700
  • Day's Range 7.86 - 8.08
  • 52 Week Range 5.80 - 11.97
  • Volume 2,978,820
  • Avg. Volume 4,052,622
  • Market Cap (intraday) 1.322B
  • Beta (5Y Monthly) 2.65
  • PE Ratio (TTM) 3.12
  • EPS (TTM) 2.58
  • Earnings Date May 6, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 14.00

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

www.novavax.com

749

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: NVAX

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NVAX
19.64%
S&P 500 (^GSPC)
5.62%

1-Year Return

NVAX
25.43%
S&P 500 (^GSPC)
29.01%

3-Year Return

NVAX
4.15%
S&P 500 (^GSPC)
73.47%

5-Year Return

NVAX
96.61%
S&P 500 (^GSPC)
72.92%

Earnings Trends: NVAX

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 147.14M
Earnings 17.53M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-200M
0
200M
400M
600M

Analyst Insights: NVAX

View More

Top Analyst

Cantor Fitzgerald
72/100
Latest Rating
Overweight

Analyst Price Targets

7.00
14.00 Average
8.04 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 2/27/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 11 -> 16

Statistics: NVAX

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    1.32B

  • Enterprise Value

    835.72M

  • Trailing P/E

    3.12

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.24

  • Price/Book (mrq)

    33.20

  • Enterprise Value/Revenue

    0.74

  • Enterprise Value/EBITDA

    1.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    39.19%

  • Return on Assets (ttm)

    25.72%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.12B

  • Net Income Avi to Common (ttm)

    440.3M

  • Diluted EPS (ttm)

    2.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    735.08M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -331.94M

Compare To: NVAX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: NVAX

Fair Value

8.04 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: